ArticleTranslational animal science2026
Enhancing steer growth and efficiency through growth promoting technologies.
Article in Translational animal science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angus-cross (216; 292 ± 22 kg) steers were used to understand the implications of growth promoting technologies on measures of cattle growth, serum metabolites, and nitrogen excretion. Steers were blocked by BW into heavy (16 pens) and light (20 pens), with 6 steers per pen. One of four treatments was applied to each pen. Treatments (TRT) consisted of (i) no implant or β-adrenergic agonist (β-AA; CON), (ii) implants (IMP: Synovex Choice: 100 mg trenbolone acetate, 14 mg estradiol benzoate [d 0]; Synovex Plus: 200 mg trenbolone acetate, 28 mg estradiol benzoate [d 69]), (iii) IMP + β3-agonist lubabegron fumarate (LUB: 36 mg/steer daily for 53 d, 4-d withdrawal), (iv) IMP + β1-agonist ractopamine hydrochloride (RAC: 300 mg/steer daily for 31 d). From terminal implant onwards, study days were held consistent to days relative to harvest for each block. Body weights were recorded and blood was collected on 1 steer per pen on days -1, 0, 69, 98, 116, 141, and 172. Serum urea nitrogen (SUN), glucose, insulin, and non-esterified fatty acids (NEFA) were analyzed. Insulin sensitivity and urinary nitrogen excretion was estimated. Carcass data were collected following a 48-h chill. Proc Mixed (SAS) was used to analyze data using treatment and block as fixed effects, serum metabolite data were analyzed as repeated measures (day as repeated). Final body weight, average daily gain, dry matter intake, and gain: feed were greater with the use of growth promoting technologies (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.